Cost-efficiency modeling of conversion to biosimilar rituximab-based R-CHOP in diffuse large B-cell lymphoma in medicare
Authors:
Open Access
- 6 April 2026
- journal article
- research article
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 29 (1) , 1089-1098
Abstract
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma (NHL) with an incidence rate of about 6 per 100,000 in the general United States (U.S.) population, and an e...Keywords
Funding Information
- Pfizer
This publication has 25 references indexed in Scilit:
- Real‐world patient characteristics, treatment patterns, and treatment outcomes of patients with diffuse large B‐cell lymphoma by line of therapyCancer Medicine, 2024
- Conversion to supportive care with biosimilar pegfilgrastim-cbqv enables budget-neutral expanded access to R-CHOP treatment in non-Hodgkin lymphomaLeukemia Research, 2021
- Cost-efficiency and expanded access of prophylaxis for chemotherapy-induced (febrile) neutropenia: economic simulation analysis for the US of conversion from reference pegfilgrastim to biosimilar pegfilgrastim-cbqvJournal of Medical Economics, 2020
- Recent survival trends in diffuse large B‐cell lymphoma––Have we made any progress beyond rituximab?Cancer Medicine, 2020
- Economic modeling for the US of the cost-efficiency and associated expanded treatment access of conversion to biosimilar pegfilgrastim-bmez from reference pegfilgrastimJournal of Medical Economics, 2020
- Extension Study of PF‐05280586, a Potential Rituximab Biosimilar, Versus Rituximab in Subjects With Active Rheumatoid ArthritisArthritis Care & Research, 2018
- Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropeniaJournal of Medical Economics, 2017
- Budget Impact Analysis—Principles of Good Practice: Report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task ForceValue in Health, 2014
- Ten-Year Relative Survival and Causes of Death in Elderly Patients Treated With R-CHOP or CHOP in the GELA LNH-985 TrialClinical Lymphoma Myeloma and Leukemia, 2012
- CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell LymphomaNew England Journal of Medicine, 2002